NCT05381142 - A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

July 11, 2022

Study Completion Date

July 11, 2022

Conditions

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenHot FlashesHealthy Volunteers

Interventions

DRUG

Elinzanetant (BAY3427080)

Elinzanetant will be administered as a single dose on Study Day 1 and a multiple dose once daily for another 6 consecutive days on Study Day 8 to Study Day 13.

DRUG

Placebo

Matching placebo will be administered the same as Elinzanetant (BAY3427080)

Trial Locations (1)

510405

The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou